Prostate cancer is often slowly progressive, and it can be difficult to treat with conventional cytotoxic drugs. Nonsteroidal antiinflammatory drugs inhibit the development of prostate cancer, but the mechanism of chemoprevention is unknown. Here, we show that the R-enantiomer of the nonsteroidal antiinflammatory drug etodolac inhibited tumor development and metastasis in the transgenic mouse adenocarcinoma of the prostate (TRAMP) model, by selective induction of apoptosis in the tumor cells. This proapoptotic effect was associated with loss of the retinoid X receptor (RXR␣) protein in the adenocarcinoma cells, but not in normal prostatic epithelium. R-etodolac specifically bound recombinant RXR␣, inhibited RXR␣ transcriptional activity, and induced its degradation by a ubiquitin and proteasome-dependent pathway. The apoptotic effect of R-etodolac could be controlled by manipulating cellular RXR␣ levels. These results document that pharmacologic antagonism of RXR␣ transactivation is achievable and can have profound inhibitory effects in cancer development.
S
everal epidemiological studies have shown that the use of nonsteroidal antiinflammatory drugs (NSAIDs) is associated with a reduced incidence of clinically detectable prostate cancer (1) (2) (3) . The side effects of cyclooxygenase (COX) inhibitors preclude the use of these agents in many elderly men (4) . Thus, there is a major need to determine whether there are chemopreventative, and antimetastatic effects of NSAIDs that can be separated from COX inhibition. Controversy has permeated this field, because many of the COX-independent actions of NSAIDs are measurable only at concentrations that are not safely achievable in vivo, and because the members of this structurally diverse group of drugs are metabolized extensively and can exert different mechanisms of action (5, 6) .
Various NSAIDs have been demonstrated to induce apoptosis in malignant cells (7) (8) (9) . Etodolac is a commercially available NSAID containing a racemic mixture, in which the S-enantiomer has COX inhibitory activity, whereas the R-enantiomer does not (10) . Unlike all other chiral NSAIDs, the two enantiomers of etodolac are not metabolically interconvertible. Moreover, the R-enantiomer is metabolized much more slowly than the S-enantiomer, and it accumulates to 10-fold higher concentrations than the S-enantiomer in plasma (11) . In a recent study, sufficient plasma levels of R-etodolac were achieved after oral gavage in a xenograft prostate cancer model to diminish the growth of the transplanted tumor (12) .
The in vivo effect of R-etodolac was associated with enhancement of peroxisome proliferator-activated receptor ␥ (PPAR␥) transactivation (12) . PPAR␥, as well as other nuclear hormone receptors, forms heterodimers with the retinoid X receptor ␣ (RXR␣) (13, 14) , which has been implicated in the pathogenesis of prostate cancer (15) . The effect of RXR␣ may be due to its induction of apoptosis through its interaction with other proteins (16) (17) (18) (19) . An activating ligand of RXR␣, 9-cis-retinoic acid (RA), is a lipophilic acid similar to R-etodolac. Thus, we hypothesized that the COXindependent effects of R-etodolac in malignant prostate cells might be attributed to its binding and modulation of RXR␣ activities.
Here, we show that R-etodolac induced apoptosis of prostate cancer cells, but not normal prostatic epithelial cells. The Retodolac-induced apoptosis was associated with reduction of RXR␣ levels selectively in the tumor cells. Direct interaction of R-etodolac and RXR␣ was demonstrated by in vitro binding of radiolabeled R-etodolac with the purified recombinant ligand-binding domain (LBD) of RXR␣ and the ability of the drug to protect RXR␣ protein from trypsin digestion. In intact cells, R-etodolac antagonized RXR␣ transcriptional activity and induced its ubiquitination and degradation. Furthermore, suppression of RXR␣ expression reduced the apoptotic effect of R-etodolac. These results demonstrate that RXR␣ acts as a receptor that mediates the COXindependent anticancer effects of R-etodolac.
Materials and Methods
Drug Preparation. R-etodolac was prepared from pharmaceuticalgrade tablets of racemic etodolac to a purity of Ͼ97% as described (see Supporting Materials and Methods, which is published as supporting information on the PNAS web site) (20) . The drug was tritiated by Sibtech (Newington, CT) and purified with HPLC. The resulting material had a specific activity of 20-25 Ci (1 Ci ϭ 37 GBq)͞mmol, and it was stored in acetonitrile at a concentration of 0.45 mCi͞ml at Ϫ20°C. The RXR-selective retinoids SR11237, SR11345, and SR11246 were described in ref. 21 and provided by M. Dawson (The Burnham Institute). Staurosporine, MG-132 (Calbiochem) and 9-cis-RA (Sigma) were purchased commercially.
et Cellulaire, College de France, Illkirch, France) (22) . See Supporting Materials and Methods for details.
Murine Studies. Transgenic mouse adenocarcinoma of the prostate (TRAMP) and C57BL͞6 mice were purchased from The Jackson Laboratory and bred at UCSD. All animal protocols received prior approval by the institutional review board. Plasma R-etodolac levels were measured on a group of seven 15-week-old C57BL͞6 male mice who were fed R-etodolac (1.25 mg͞kg) chow for 2 weeks by a bioanalytical LC͞MS-based method developed by Maxxam Analytics (Mississauga, ON, Canada). Chiral HPLC (23) was used to confirm the lack of R-to S-etodolac in vivo interconversion.
We started 46 male TRAMP mice at 9-12 weeks of age on chow with R-etodolac 1.25 mg͞kg or control food (prepared by Dyets, Bethlehem, PA) randomized by cage. At 30 weeks, or after appearance of a gross palpable tumor mass, the animals were sacrificed and necropsies were performed. The urogential system, the periaortic lymph nodes, and the major organs were removed and weighed. The prostatic tissues were dissected and separated into individual lobes and weighed. Tissues were fixed in 10% formalin embedded in paraffin, sectioned in step sections at 50-m intervals, and stained with hematoxylin and eosin. The prostate sections were scored for carcinoma grade on a 1-6 scale (see Supporting Materials and Methods). The liver, lung, and lymph node sections were scored for the presence or absence of tumor. The weights of the different tissues, and the frequencies of metastases, in the drug treated and control animals were compared by the Mann-Whitney test or Fisher's exact test, with P Ͻ 0.05 considered significant.
Ligand Binding. The human RXR␣ LBD (223-462), prepared as a polyhistidine-tagged fusion protein in pET15b (Novagen) (1 g), was incubated with radiolabeled ligand in the presence of different concentrations of unlabeled 9-cis-RA or R-etodolac at 4°C for 14 h. The RXR␣ LBD was captured by nickel-coated beads. Bound radiolabeled ligand was determined in a scintillation counter.
Immunohistochemistry and Apoptosis Assays. For 2 weeks, we fed 6-to 7-month-old TRAMP mice R-etodolac supplemented or control chow. The prostates were removed, and serial frozen sections were assayed for terminal deoxyribonucleotidyl transferase (TdT; TUNEL; Chemicon) or stained with anti-human RXR␣ (D20; Santa Cruz Biotechnology), followed by staining with DAPI (50 g͞ml; Sigma) containing DNase-free RNase A (100 g͞ml; Boehringer Mannheim) to visualize the nuclei and examined by fluorescence microscopy (18, 19, 24) . Single-cell apoptosis was detected in vitro by removing adherent cells from the plate with 5 mM EDTA, incubating them with annexin-V-phycoerythrin (BD PharMingen) and analyzing by flow cytometry.
Transient-Transfection Assay. Expression vectors for RXR␣, RA receptor ␤ (RAR␤), hemagglutinin (HA)-ubiquitin, and reporter gene ␤RARE-tk-chloramphenicol transferase (CAT) were prepared and transfected as described (25, 26) . We mixed Ϸ300 ng of reporter plasmid, 50 ng of ␤-gal expression vector (pCH 110; Pharmacia), and vector expressing RXR␣ with carrier DNA (pBluescript) to give 1.0 g of total DNA per well. CAT activity was normalized for transfection efficiency on the basis of cotransfected ␤-gal gene activity. Transfected cell lysates were separated by SDS͞PAGE and immunoblotted (see Supporting Materials and Methods). The prostates were not dissectible in mice that had gross tumor masses (two in the treatment group and six in the control group). The weights of the control urogenital tracts, lateral, and dorsal prostates were significantly higher than those of the treated group, as determined by the Mann-Whitney test.
from Dharmacon. A 10-l aliquot of 20 M siRNA per well was transfected into cells in six-well plates by using Lipofectamine Plus (Invitrogen) (17) .
Results

Antiproliferative and Proapoptotic Effects of R-Etodolac. R-etodolac
dose dependently inhibited the proliferation of LNCaP prostate cancer cells and PrEC normal human prostatic epithelial cells (see Fig. 7 , which is published as supporting information on the PNAS web site). At 72 h, the ID 50 values were Ϸ150 M for LNCaP, compared with Ϸ400 M for PrEC (Fig. 7a) . Concentrations of R-etodolac of Ͼ500 M induced apoptosis in primary prostate cancer explants ( Fig. 7 b-e). In the latter instance, the malignant cells displayed shrunken and pyknotic nuclei, whereas the nuclei from the adjacent normal prostatic epithelium appeared morphologically normal.
Activity of R-Etodolac in the TRAMP Model. Preliminary dose-ranging pharmacokinetic data showed that plasma concentrations of 370 Ϯ 30 M could be achieved by supplementing a standard mouse chow diet with 1.25 mg͞kg R-etodolac for 2 weeks. Chiral HPLC revealed no detectable conversion of R-etodolac to the S-stereoisomer. Therefore, in vivo experiments in the TRAMP mouse model were undertaken under these conditions. Male TRAMP mice develop histological intraepithelial neoplasia of the prostate by 8-12 weeks of age that progresses to adenocarcinoma with distant site metastases by 24-28 weeks of age (27, 28) . Control chow or diets supplemented with R-etodolac were initiated at 9-12 weeks. By 30 weeks, nearly all of the prostates in the R-etodolac treated and untreated groups had macroscopic evidence of tumor (Table 1) . However, both the average tumor mass (Fig. 1 ) and the frequencies of metastases (Table 1) were significantly lower in the R-etodolactreated animals. Histological evaluation of the excised tissues confirmed the anti-metastatic effects of the drug and did not show evidence of drug toxicity (Fig. 2 a-l) . Collectively, these data indicated that R-etodolac retarded the progression and metastasis of prostate cancer in the TRAMP system.
R-Etodolac Selectively Induces Apoptosis in Cancerous Prostates.
To determine whether R-etodolac treatment resulted in apoptosis in vivo, 6-to 7-month-old male TRAMP and nontransgenic littermates were fed with R-etodolac or control chow for 2 weeks and (m) Induction of tumor cell apoptosis by R-etodolac. For 2 weeks, we fed 6-to 7-month-old TRAMP mice with R-etodolac-supplemented chow or control chow, and they were then sacrificed. The prostate lobes were removed and frozen in OCT, sectioned, and subjected to TUNEL staining (red) and DAPI (to visualize nuclei) (ϫ200). Extensive apoptosis (TUNEL-positive) was detected in the prostates of R-etodolac-fed TRAMP mice compared with control chow-fed mice. sacrificed, and the prostates were examined for apoptosis. Extensive apoptosis in the prostates of drug-treated TRAMP mice was seen on TUNEL staining of frozen sections, whereas no apoptosis was seen in mice fed with control chow (Fig. 2m) . No apoptosis was detectable in prostates of nontransgenic mice fed with R-etodolac.
RXR␣ Is Required for the Apoptotic Effect of R-Etodolac.
A previous study demonstrated that PPAR␥ was associated with the apoptosis induced by R-etodolac (12) . PPAR␥ heterodimerizes with RXR␣, and thus, we examined its possible role. Transfection of RXR␣-specific siRNA, but not control siRNA, almost completely inhibited RXR␣ expression in LNCaP cells (Fig. 3a) . The apoptotic effect of R-etodolac in RXR␣ siRNA-transfected cells was substantially diminished (Fig. 3b) . CV-1 cells lack detectable levels of RXR␣ (25, 26) , and they were relatively resistant to R-etodolac-induced apoptosis. However, transfection of CV-1 cells with RXR␣, but not a control vector, reversed this drug-resistant phenotype (Fig. 3c) . Similarly RXR␣ Ϫ/Ϫ F9 embryonal cells did not undergo apoptosis with drug treatment compared with the extensive apoptosis in wild-type F9 cells (Fig. 3d) . Thus, RXR␣ is required for the apoptotic effect of R-etodolac.
R-Etodolac Binds to RXR␣. To investigate whether R-etodolac could bind RXR␣, a ligand competition assay with [
3 H]9-cis-RA was used. Both unlabeled 9-cis-RA and R-etodolac displaced [ 3 H]9-cis-RA bound to RXR␣ LBD (Fig. 4a) , with an IC 50 value of Ϸ200 M for R-etodolac. Furthermore, [ 3 H]R-etodolac directly bound the RXR␣ LBD, and this binding was competitively inhibited by both unlabeled R-etodolac and 9-cis-RA (Fig. 4 b  and c) .
R-Etodolac Binding Induces Conformational Change in RXR␣.
Binding of ligands to their receptors often induces changes in susceptibility to proteolysis (13, 14) . Digestion of the RXR␣ LBD with a low concentration of trypsin (3 g͞ml) yielded a proteolytic fragment of Ϸ20 kDa, whreeas higher concentrations of trypsin (10 or 30 g͞ml) completely digested the LBD (see Fig. 8 , which is published as supporting information on the PNAS web site). Preincubation of the RXR␣ LBD with 9-cis-RA did not alter its sensitivity to trypsin digestion, consistent with previous studies (29) . However, incuba- tion of the RXR␣ LBD with R-etodolac before trypsin digestion (3 g͞ml) resulted in a different digestion pattern, with two new proteolytic fragments of Ϸ18 kDa, in contrast to the lack of protection detected with PPAR␥ (Fig. 8) .
R-Etodolac Modulates RXR␣ Transcriptional Activity. To test whether R-etodolac binding modulated RXR␣ transcriptional activity, a reporter gene containing RXR␣ homodimer-responsive elements, (TREpal) 2 -tk-CAT (26) , was transfected with a RXR␣ expression vector into CV-1 cells. Treatment of cells with 9-cis-RA strongly induced reporter gene activity, whereas treatment with R-etodolac did not (Fig. 5a) . However, when transfected cells were treated with 9-cis-RA, the addition of R-etodolac dose dependently reduced the transcriptional activity of RXR␣.
We investigated whether R-etodolac inhibited transactivation of endogenous RXR␣. An RA-response element (␤RARE) in the RAR␤ promoter, which binds various RXR-containing heterodimers including RXR͞RAR and RXR͞PPAR␥ (26, 30, 31) , was transfected into ZR-75-1 breast cancer cells. Reporter activity was induced by all-trans-RA, presumably because of binding of endogenous RXR͞RAR heterodimer. Cotreatment with Retodolac suppressed all-trans-RA-induced reporter activity in a R-etodolac concentration-dependent manner, suggesting that Retodolac inhibited transcriptional activity of endogenous RXR͞ RAR heterodimers (Fig. 5b) . The transcriptional effect of Retodolac on RXR␣ was confirmed by analyzing its effect on the expression of RAR␤. Treatment of ZR-75-1 cells with all-trans-RA strongly induced the endogenous expression of RAR␤ (Fig. 5c) , which was completely inhibited by R-etodolac, consistent with the inhibitory effect of R-etodolac on the ␤RARE reporter gene (Fig.  5b) . To determine the effect of R-etodolac on RXR͞PPAR␥ heterodimer activity, ZR-75-1 cells were stimulated with the PPAR␥ ligand ciglitazone and the RXR␣ ligand SR11237 in the presence or absence of R-etodolac (Fig. 5 d and e) (30) . The induction of endogenous RAR␤ expression by the two drugs in combination was abolished by R-etodolac cotreatment (Fig. 5e) .
Loss of RXR␣ Expression After R-Etodolac Treatment. Subcellular localization of RXR␣ plays a role in the regulation of apoptosis (17) . To analyze whether R-etodolac treatment altered RXR␣ subcellular localization, in vivo immunostaining of RXR␣ was performed on the prostate tissues from male TRAMP and nontransgenic littermates fed with R-etodolac or control chow. RXR␣ was predominantly localized in the nucleus in the prostates of the nontransgenic mice fed with or without R-etodolac chow (Fig. 6a) . TRAMP mice fed with control chow displayed similar RXR␣ nuclear staining. However, RXR␣ staining was greatly reduced in prostates of TRAMP mice fed with R-etodolac.
RXR␣ protein levels in LNCaP cells were also markedly reduced after treatment with R-etodolac (Fig. 6b) . R-etodolac-induced degradation of RXR␣ levels was completely prevented by the proteosome inhibitor MG132 (Fig. 6b) . Proteins are often ubiquitinated before degradation by proteasomes (32) . Thus, we determined whether R-etodolac induced ubiquitination of RXR␣. Myctagged RXR␣ was cotransfected into HEK 293T cells with or without an expression vector for HA-tagged ubiquitin, followed by treatment with R-etodolac in the presence of MG132. Immunoprecipitation with anti-myc antibody, followed by immunoblotting with an anti-HA antibody, revealed that RXR␣ was extensively ubiquitinated after R-etodolac treatment (Fig. 6c) but not after treatment with the synthetic RXR␣ ligands SR11345 and SR11246 (Fig. 6d) . Instead, these ligands abrogated R-etodolac-induced RXR␣ ubiquitination (Fig. 6e) , probably because of their competition for binding to RXR␣. Collectively, these results demonstrate that R-etodolac binds RXR␣ and induces its degradation in a proteasome-dependent manner.
Discussion
The standard therapy for progressive prostate cancer is androgen ablation. However, many patients become unresponsive and develop metastatic disease (33) . Thus, there is a compelling need for the development of unconventional agents that can delay the progression of prostate cancer. In this article, we report that chronic oral administration of the COX-inactive R-stereoisomer of the common NSAID etodolac inhibited tumor expansion and metas- tasis in the TRAMP model. By analogy, R-etodolac could be a prospective agent for the treatment of human prostate cancer.
In the TRAMP model, treatment with the COX-2 selective agent celecoxib or the R-enantiomer of the NSAID flurbiprofen resulted in a significantly lower primary-tumor incidence and a reduced incidence of metastases (34, 35) . However, both of these drugs may have exerted their effect by active COX inhibition because 15% of the R-flurbiprofen was converted to the active COX inhibitor S-flurbiprofen by 2-4 h after administration. In contrast, the stereoisomers of the conformationally rigid etodolac molecule, unlike all other approved racemic NSAIDs, cannot undergo chiral transformation under physiologic conditions. Indeed, S-etodolac was undetectable in the plasmas of the mice given diets supplemented with the R-stereoisomer. Hence, the cytostatic and antimetastatic effects of R-etodolac in the TRAMP model must be attributed to the drug or to a metabolite.
The results presented here reveal an unexpected function of RXR␣ as a mediator of the apoptotic effect of R-etodolac. A recent study (12) demonstrated that inhibition of prostate tumor growth by R-etodolac was associated with initial enhancement of PPAR␥ transcriptional activity, followed by degradation of the receptor (12) . However, ligand competition and direct binding assays using PPAR␥ recombinant protein failed to demonstrate any direct binding of R-etodolac to PPAR␥ (data not shown). Because PPAR␥ activity depends on heterodimerization with RXR␣, it is possible that modulation of PPAR␥ and degradation by R-etodolac is mediated by its binding to RXR␣. Antagonists of RXR homodimers are known to function as agonists of RXR͞PPAR␥ heterodimers (36, 37) .
Exactly how RXR␣ mediates the apoptotic effects of R-etodolac remains unknown. It is unlikely that R-etodolac exerts its anticancer effect through its inhibition of RXR␣ transactivation (Fig. 5 ) because many RXR␣ agonists potently inhibit the growth of prostate cancer cells. However, the binding of RXR␣ by R-etodolac could affect the function and stability of several nuclear receptors that dimerize with RXR␣, including PPAR␥ and Nur77.
Our results demonstrate that R-etodolac induced apoptosis of prostate cancer, but not normal epithelium ( Fig. 2 and 7) . The contrasting effects might be attributable to differences in RXR␣ posttranslational processing in cancer and normal cells (38) . In this regard, it was reported recently that RXR␣ was phosphorylated by MAP kinase in surgically resected hepatocellular carcinoma samples but not in the corresponding noncancerous surrounding tissues (39) .
A recent population-based study of NSAID use and prostate cancer revealed that the relative odds of prostate cancer among the drug users was 0.2 (95% confidence interval 0.1-0.5) in men during the eighth decade of life but only 0.9 in men during the sixth decade, compared with similarly aged men who did not use NSAIDs (3). The stronger effect among older men raised the possibility that NSAIDs may prevent the progression of prostate cancer from latent to clinical disease, rather than reduce the frequency of primary lesions. The experimental results with R-etodolac in the TRAMP model of prostate cancer display many parallels with the human population data. Thus, it is possible that R-etodolac could represent a potential approach toward preventing the progression of hormone refractory prostate cancer, especially in the very elderly patients who are not candidates for cytotoxic therapy.
